Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1996
Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor. Here we investigated the efficacy of sequential intravesical therapy with EPI and BCG to EPI or BCG alone in patients with transitional cell carcinoma of bladder cancer after surgical management.
Epistemonikos ID: f73d8f7348f3d42e68edf20dd9fcbba36145e9c4
First added on: May 04, 2024